Home » Mixed Phase II Results With Isis-CRPRx in RA Patients
Mixed Phase II Results With Isis-CRPRx in RA Patients
August 5, 2013
A Phase II study of patients with rheumatoid arthritis, conducted by Isis Pharmaceuticals, showed that patients treated with Isis-CRPRx showed a 67 percent decrease in C-reactive protein.
The Pharma Letter
The Pharma Letter
Upcoming Events
-
21Oct